, Tracking Stock Market Picks
Enter Symbol:
Cyclacel Pharmaceuticals, Inc. (CYCC) [hlAlert]

down 97.49 %

Cyclacel Pharmaceuticals, Inc. (CYCC) rated Buy with price target $7 by Needham & Co

Posted on: Wednesday,  Mar 12, 2008  9:25 AM ET by Needham

Needham rated Buy Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC) on 03/12/2008, when the stock price was $20.72. Since
then, Cyclacel Pharmaceuticals, Inc. has lost 97.49% as of 08/27/2015's recent price of $0.52.
If you would have followed this Needham's recommendation on CYCC, you would have lost 97.49% of your investment in 2724 days.

Cyclacel Pharmaceuticals, Inc. (Cyclacel) is a development-stage biopharmaceutical company engaged in the discovery, development and commercialization of mechanism-targeted drugs to treat human cancers and other serious disorders. The Company markets, directly in the United States, Xclair Cream for radiation dermatitis, and Numoisyn Liquid and Numoisyn Lozenges for xerostomia through its wholly owned subsidiary, ALIGN Pharmaceuticals, LLC (ALIGN). Cyclacel focuses primarily on the development of orally available anticancer agents that target the cell cycle with the aim of slowing the progression or shrinking the size of tumors. The Company has been focusing on the cell cycle since its inception. On January 13, 2009, it announced that the Company began treating patients in a Phase II, open label, single arm, multicenter clinical trial of sapacitabine in patients with non-small cell lung cancer (NSCLC) who have had one prior chemotherapy.

Needham & Company, LLC focuses on emerging growth companies in technology, biotechnology and life sciences. The firm's research goal is to service the needs of growth-oriented institutional clients. Needham & Company has established itself as a premier specialty investment bank providing timely and valuable analysis on companies that are under-covered by the majority of Wall Street firms.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
3/12/2008 9:25 AM Buy
20.72 49.00
as of 8/27/2015
1 Week down  -14.75 %
1 Month down  -42.22 %
3 Months down  -37.34 %
1 YTD down  -87.06 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy